Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency.


Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
07 May 2024
Historique:
revised: 19 03 2024
received: 29 09 2023
accepted: 22 03 2024
medline: 7 5 2024
pubmed: 7 5 2024
entrez: 7 5 2024
Statut: aheadofprint

Résumé

Clinically meaningful benefits in the signs, symptoms, and impacts of #PKDeficiency as assessed by disease-specific patient-reported outcome measures were observed in mitapivat-treated adult patients in two phase 3 clinical trials.

Identifiants

pubmed: 38712615
doi: 10.1002/ajh.27312
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agios Pharmaceuticals

Informations de copyright

© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Références

Grace RF, Bianchi P, van Beers EJ, et al. Clinical spectrum of pyruvate kinase deficiency: data from the pyruvate kinase deficiency natural history study. Blood. 2018;131:2183‐2192.
Al‐Samkari H, van Beers EJ, Morton DH, et al. Health‐related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Adv. 2022;6:1844‐1853.
Andrae DA, Grace RF, Jewett A, et al. Psychometric validation of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment in adults in the phase 3 ACTIVATE trial. J Patient Rep Outcomes. 2023;7:112.
Agios Pharmaceuticals Inc. Pyrukynd. Prescribing information. 2022. Accessed June 15, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf
Al‐Samkari H, Galactéros F, Glenthøj A, et al. Mitapivat versus placebo for pyruvate kinase deficiency. N Engl J Med. 2022;386:1432‐1442.
Glenthøj A, van Beers EJ, Al‐Samkari H, et al. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE‐T): a multicentre, open‐label, single‐arm, phase 3 trial. Lancet Haematol. 2022;9:e724‐e732.

Auteurs

Kevin H M Kuo (KHM)

Division of Hematology, University of Toronto, Toronto, Ontario, Canada.

Rachael F Grace (RF)

Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Harvard Medical School, Boston, Massachusetts, USA.

Eduard J van Beers (EJ)

Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Wilma Barcellini (W)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Andreas Glenthøj (A)

Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Susanne Holzhauer (S)

Department of Pediatric Hematology and Oncology, Charité University Medicine, Berlin, Germany.

Vanessa Beynon (V)

Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

Susan Morris (S)

Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

Junlong Li (J)

Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

Erin Zagadailov (E)

Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

Parija Patel (P)

Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

Hanny Al-Samkari (H)

Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Classifications MeSH